Does the media prefer JAZZ or AXSM?

In the previous week, Axsome Therapeutics had 4 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 17 mentions for Axsome Therapeutics and 13 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.04 beat Axsome Therapeutics' score of 0.23 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Axsome Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer RVMD or AXSM?

In the previous week, Axsome Therapeutics had 5 more articles in the media than Revolution Medicines. MarketBeat recorded 17 mentions for Axsome Therapeutics and 12 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.52 beat Axsome Therapeutics' score of 0.23 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to ONC or AXSM?

In the previous week, Axsome Therapeutics had 10 more articles in the media than BeOne Medicines. MarketBeat recorded 17 mentions for Axsome Therapeutics and 7 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 1.00 beat Axsome Therapeutics' score of 0.23 indicating that BeOne Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor AXSM or BNTX?

In the previous week, Axsome Therapeutics had 11 more articles in the media than BioNTech. MarketBeat recorded 17 mentions for Axsome Therapeutics and 6 mentions for BioNTech. BioNTech's average media sentiment score of 0.69 beat Axsome Therapeutics' score of 0.23 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Axsome Therapeutics (AXSM) Competitors

$245.64 +10.50 (+4.47%)

Closing price 04:00 PM Eastern

Extended Trading

$245.71 +0.07 (+0.03%)

As of 07:55 PM Eastern

Compare

AXSM vs. JAZZ, TEVA, RVMD, ONC, and BNTX

Should you buy Axsome Therapeutics stock or one of its competitors? MarketBeat compares Axsome Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Axsome Therapeutics include Jazz Pharmaceuticals (JAZZ), Teva Pharmaceutical Industries (TEVA), Revolution Medicines (RVMD), BeOne Medicines (ONC), and BioNTech (BNTX). These companies are all part of the "medical" sector.

How does Axsome Therapeutics compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Axsome Therapeutics (NASDAQ:AXSM) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Jazz Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

Axsome Therapeutics has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.37	-$356.15M	-$0.02	N/A
Axsome Therapeutics	$638.50M	19.80	-$183.17M	-$3.73	N/A

In the previous week, Axsome Therapeutics had 4 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 17 mentions for Axsome Therapeutics and 13 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.04 beat Axsome Therapeutics' score of 0.23 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Axsome Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Jazz Pharmaceuticals presently has a consensus target price of $244.18, indicating a potential upside of 6.54%. Axsome Therapeutics has a consensus target price of $251.26, indicating a potential upside of 2.29%. Given Jazz Pharmaceuticals' higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.84
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

Jazz Pharmaceuticals has a net margin of 0.66% compared to Axsome Therapeutics' net margin of -26.59%. Jazz Pharmaceuticals' return on equity of 14.56% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	0.66%	14.56%	5.25%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 4.3% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Axsome Therapeutics beats Jazz Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Axsome Therapeutics (NASDAQ:AXSM) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Teva Pharmaceutical Industries has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

In the previous week, Teva Pharmaceutical Industries had 16 more articles in the media than Axsome Therapeutics. MarketBeat recorded 33 mentions for Teva Pharmaceutical Industries and 17 mentions for Axsome Therapeutics. Teva Pharmaceutical Industries' average media sentiment score of 1.29 beat Axsome Therapeutics' score of 0.23 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	27 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Axsome Therapeutics' net margin of -26.59%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Teva Pharmaceutical Industries has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.29	$1.41B	$1.33	25.83
Axsome Therapeutics	$638.50M	19.80	-$183.17M	-$3.73	N/A

Teva Pharmaceutical Industries currently has a consensus price target of $41.78, indicating a potential upside of 21.62%. Axsome Therapeutics has a consensus price target of $251.26, indicating a potential upside of 2.29%. Given Teva Pharmaceutical Industries' higher probable upside, equities analysts plainly believe Teva Pharmaceutical Industries is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

Summary

Teva Pharmaceutical Industries beats Axsome Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Axsome Therapeutics (NASDAQ:AXSM) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Revolution Medicines has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Revolution Medicines' return on equity of -83.22% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Revolution Medicines presently has a consensus target price of $123.72, indicating a potential downside of 17.27%. Axsome Therapeutics has a consensus target price of $251.26, indicating a potential upside of 2.29%. Given Axsome Therapeutics' higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

In the previous week, Axsome Therapeutics had 5 more articles in the media than Revolution Medicines. MarketBeat recorded 17 mentions for Axsome Therapeutics and 12 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.52 beat Axsome Therapeutics' score of 0.23 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Revolution Medicines has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Axsome Therapeutics has higher revenue and earnings than Revolution Medicines. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	2,745.62	-$1.13B	-$7.07	N/A
Axsome Therapeutics	$638.50M	19.80	-$183.17M	-$3.73	N/A

Summary

Revolution Medicines beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Axsome Therapeutics (NASDAQ:AXSM) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

In the previous week, Axsome Therapeutics had 10 more articles in the media than BeOne Medicines. MarketBeat recorded 17 mentions for Axsome Therapeutics and 7 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 1.00 beat Axsome Therapeutics' score of 0.23 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

BeOne Medicines presently has a consensus price target of $390.00, indicating a potential upside of 45.43%. Axsome Therapeutics has a consensus price target of $251.26, indicating a potential upside of 2.29%. Given BeOne Medicines' stronger consensus rating and higher probable upside, analysts plainly believe BeOne Medicines is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

BeOne Medicines has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

BeOne Medicines has a net margin of 8.94% compared to Axsome Therapeutics' net margin of -26.59%. BeOne Medicines' return on equity of 12.06% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

BeOne Medicines has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	5.51	$286.93M	$4.47	59.99
Axsome Therapeutics	$638.50M	19.80	-$183.17M	-$3.73	N/A

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

BeOne Medicines beats Axsome Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to BioNTech?

Axsome Therapeutics (NASDAQ:AXSM) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Axsome Therapeutics has a net margin of -26.59% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
BioNTech	-44.39%	-5.30%	-4.62%

Axsome Therapeutics has higher earnings, but lower revenue than BioNTech. Axsome Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	19.80	-$183.17M	-$3.73	N/A
BioNTech	$3.25B	6.74	-$1.29B	-$5.88	N/A

Axsome Therapeutics has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market.

Axsome Therapeutics presently has a consensus price target of $251.26, suggesting a potential upside of 2.29%. BioNTech has a consensus price target of $129.56, suggesting a potential upside of 49.78%. Given BioNTech's higher possible upside, analysts clearly believe BioNTech is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Axsome Therapeutics had 11 more articles in the media than BioNTech. MarketBeat recorded 17 mentions for Axsome Therapeutics and 6 mentions for BioNTech. BioNTech's average media sentiment score of 0.69 beat Axsome Therapeutics' score of 0.23 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Axsome Therapeutics beats BioNTech on 9 of the 16 factors compared between the two stocks.

Get Axsome Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AXSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AXSM vs. The Competition

Export

Metric	Axsome Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.10B	$3.30B	$6.64B	$12.06B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-65.86	18.68	24.75	23.76
Price / Sales	19.80	297.55	508.64	105.22
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	140.37	8.06	10.47	6.72
Net Income	-$183.17M	$23.83M	$3.56B	$337.35M
7 Day Performance	10.57%	-2.82%	-1.11%	-2.54%
1 Month Performance	13.00%	2.22%	1.28%	1.42%
1 Year Performance	123.57%	37.70%	21.20%	24.71%

Axsome Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AXSM Axsome Therapeutics	1.8517 of 5 stars	$245.64 +4.5%	$251.26 +2.3%	+110.1%	$12.10B	$638.50M	N/A	380	Insider Trade
JAZZ Jazz Pharmaceuticals	3.5391 of 5 stars	$232.04 -2.7%	$242.65 +4.6%	+108.8%	$14.97B	$4.27B	N/A	2,890	Positive News Analyst Forecast
TEVA Teva Pharmaceutical Industries	4.5561 of 5 stars	$33.24 -2.8%	$41.78 +25.7%	+87.1%	$39.31B	$17.26B	24.99	33,950	News Coverage Positive News Analyst Upgrade
RVMD Revolution Medicines	1.7287 of 5 stars	$148.49 -0.5%	$123.72 -16.7%	+261.4%	$31.73B	$11.58M	N/A	250
ONC BeOne Medicines	4.363 of 5 stars	$270.80 +0.3%	$390.00 +44.0%	+5.8%	$29.64B	$5.34B	60.58	12,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AXSM) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Axsome Therapeutics (AXSM) Competitors

AXSM vs. JAZZ, TEVA, RVMD, ONC, and BNTX

How does Axsome Therapeutics compare to Jazz Pharmaceuticals?

Summary

How does Axsome Therapeutics compare to Teva Pharmaceutical Industries?

Summary

How does Axsome Therapeutics compare to Revolution Medicines?

Summary

How does Axsome Therapeutics compare to BeOne Medicines?

Summary

How does Axsome Therapeutics compare to BioNTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXSM vs. The Competition

Axsome Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Axsome Therapeutics (AXSM) Competitors

AXSM vs. JAZZ, TEVA, RVMD, ONC, and BNTX

How does Axsome Therapeutics compare to Jazz Pharmaceuticals?

Which has more risk and volatility, JAZZ or AXSM?

Which has higher valuation and earnings, JAZZ or AXSM?

Does the media prefer JAZZ or AXSM?

Do analysts rate JAZZ or AXSM?

Is JAZZ or AXSM more profitable?

Do insiders & institutionals hold more shares of JAZZ or AXSM?

Summary

How does Axsome Therapeutics compare to Teva Pharmaceutical Industries?

Which has more volatility and risk, TEVA or AXSM?

Does the media prefer TEVA or AXSM?

Is TEVA or AXSM more profitable?

Do insiders and institutionals believe in TEVA or AXSM?

Which has preferable earnings & valuation, TEVA or AXSM?

Do analysts rate TEVA or AXSM?

Summary

How does Axsome Therapeutics compare to Revolution Medicines?

Is RVMD or AXSM more profitable?

Do analysts rate RVMD or AXSM?

Does the media prefer RVMD or AXSM?

Do institutionals & insiders believe in RVMD or AXSM?

Which has more volatility & risk, RVMD or AXSM?

Which has stronger valuation & earnings, RVMD or AXSM?

Summary

How does Axsome Therapeutics compare to BeOne Medicines?

Does the media refer more to ONC or AXSM?

Do analysts rate ONC or AXSM?

Which has more risk and volatility, ONC or AXSM?

Is ONC or AXSM more profitable?

Which has preferable valuation and earnings, ONC or AXSM?

Do institutionals and insiders believe in ONC or AXSM?

Summary

How does Axsome Therapeutics compare to BioNTech?

Is AXSM or BNTX more profitable?

Which has preferable earnings and valuation, AXSM or BNTX?

Which has more risk & volatility, AXSM or BNTX?

Do analysts recommend AXSM or BNTX?

Do institutionals & insiders have more ownership in AXSM or BNTX?

Does the media favor AXSM or BNTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXSM vs. The Competition

Axsome Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools